SCHEMBL6877246

SCHEMBL6877246

CCOC(=O)c1cnc(-c2ncccn2)nc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
LMNA P02545 3/20 0.52
MAPT P10636 2/20 0.52
MAPK1 P28482 1/20 0.52
ATM Q13315 1/20 0.52
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
TP53 P04637 1/20 0.51
KDM4E B2RXH2 3/20 0.51
CYP1A2 P05177 2/20 0.48
POLB P06746 2/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TSHR P16473 1/20 0.45
HSP90AA1 P07900 1/20 0.45
HTT P42858 1/20 0.44
HSD17B10 Q99714 2/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6877073 0.84 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL3368012 0.84 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL4849077 0.83 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL6878529 0.82 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL1866781 0.81 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL3159704 0.81 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL2538924 0.80 HSP90AA1 (0.67) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL11785304 0.80 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL959574 0.80 CSNK1D (0.54) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1
SCHEMBL762042 0.80 HSP90AA1 (0.50) ALDH1A1SMN1; SMN2LMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787539-B2 HAS ACTIVITY AS AN ANTAGONIST TO NEUROKININ 1 RECEPTORS; FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA (BPH) HOFFMANN-LA ROCHE INC. 2004-09-07 US disclosed
EP-1339698-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-03 EP disclosed
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives HOFFMANN-LA ROCHE INC. 2002-07-25 US disclosed
WO-2002042280-A2 PYRIMIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099207-A1 2,4,5,-trisubstituted pyrimidine derivatives TACR1, TACR2, P2RY2 ALDH1A1 1117/4885SMN1; SMN2 2324/4885LMNA 3868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.